Development and application of a validated HPLC method for the analysis of dissolution samples of levothyroxine sodium drug products

Journal of Pharmaceutical and Biomedical Analysis

Volumn 54, Issue 3, 2011, Pages 433-438

  Collier, J W ^a,b   Shah, R B ^b   Bryant, A R ^b   Habib, M J ^a   Khan, M A ^b   Faustino, P J ^b  

^a HOWARD UNIVERSITY   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Dissolution; Drug product; HPLC; Levothyroxine; Validation

Indexed keywords

LEVOTHYROXINE SODIUM; METHANOL;

ACCURACY; ACIDITY; ARTICLE; CHROMATOGRAPHIC COLUMN; DEVICE; DRUG SOLUBILITY; ELUTION; FLOW RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; STANDARD; TABLET; ULTRAVIOLET RADIATION; VALIDITY;

CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; EXCIPIENTS; HUMANS; INDICATORS AND REAGENTS; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SOLUBILITY; THYROID HORMONES; THYROXINE;

EID: 78149501243     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2010.08.025     Document Type: Article

References (21)

1. Gika H., Samanidou V., Papadoyannis I. Development of a validated HPLC method for the determination of iodotyrosines and iodothyronines in pharmaceuticals and biological samples using solid phase extraction. J. Chromatogr. B 2005, 814:163-172.
2. Gika H., Lammerhofer M., Papadoyannis I., Lindner W. Direct separation and quantitative analysis of thyroxine and triiodothyronine enantiomers in pharmaceuticals by high-performance liquid chromatography. J. Chromatogr. B 2004, 800:193-201.
3. Post A., Warren R. Sodium levothyroxine. Analytical Profiles of Drug Substances 1976, vol. 5:230. Academic Press, New York.
4. Won C. Kinetics of degradation of levothyroxine in aqueous solution and in solid state. Pharm. Res. 1992, 9:226-281.
5. Patel H., Stalcup A., Dansereau R., Sakr A. The effect of excipients on the stability of levothyroxine sodium pentahydrate tablets. Int. J. Pharm. 2003, 264:35-43.
6. Volpato N., Silva R., Brito A., Goncalves J., Vaisman M., Noël F. Multiple level C in vitro/in vivo correlation of dissolution profiles of two l-thyroxine tablets with pharmacokinetics data obtained from patients treated for hypothyroidism. Eur. J. Pharm. 2004, 21:655-660.
7. Shah R., Bryant A., Collier J., Habib M., Khan M. Stability indicating validated HPLC method for quantification of levothyroxine with eight degradation peaks in the presence of excipients. Int. J. Pharm. 2008, 360:77-82.
8. Gu J., Soldin O., Soldin S. Simultaneous quantification of free triiodothyronine and free thyroxine by isotope dilution tandem mass spectrometry. Clin. Biochem. 2007, 40:1386-1391.
9. Carducci C., Lucangioli S., Rodriguez V., Fernandez G. Application of extraction disks in dissolution tests of clenbuterol and levothyroxine tablets by capillary electrophoresis. J. Chromatogr. A 1996, 730:313-319.
10. Richheimer S., Amer T. Stability-indicating assay, dissolution, and content uniformity of sodium levothyroxine in tablets. J. Pharm. Sci. 1983, 72:1349-1351.
11. Rapaka R, Knight P., Prasad V. Revered-phase high-performance liquid chromatographic analysis of liothyronine sodium and levothyroxine sodium in tablet formulations: preliminary studies on dissolution and content uniformity. J. Pharm. Sci. 1981, 70:131-134.
12. Rapaka R., Roth J., Brine G., Prasad V. A simple HPLC method for the dissolution studies on levothyroxine sodium tablets. Int. J. Pharm. 1982, 12:285-294.
13. Smith D., Biesemeyer M., Yaciw C. The separation and determination of liothyronine and levothyroxine in tablets by reversed-phase high performance liquid chromatography. J. Chromatogr. Sci. 1981, 19:72-78.
14. Brower J., Toler D., Reepmeyer J. Determination of sodium levothyroxine in bulk, tablet, and injection formulations by high-performance liquid chromatography. J. Pharm. Sci. 1984, 73:1315-1317.
15. Garnick R., Burt G., Long D., Bastian J., Aldred J. High-performance liquid chromatographic assay for sodium levothyroxine in tablet formulations: content uniformity applications. J. Pharm. Sci. 1884, 73:75-77.
16. Pastor F., Milovanovic G., Todorovic M. Kinetic method for the determination of traces of thyroxine by its catalytic effect on the Mn(III) metaphosphate-As(III) reaction. Talanta 2008, 74:1556-1561.
17. Pabla D., Akhalaghi F., Zia H. A comparative pH-dissolution profile study of selected commercial levothyroxine products using inductively coupled plasma mass spectrometry. Eur. J. Pharm. Biopharm. 2009, 72:105-110.
18. Pabla D., Akhalaghi F., Zia H. Development and validation of an inductively coupled plasma mass spectrometry method for quantification of levothyroxine in dissolution studies. Rapid Commun. Mass Spectrom. 2008, 22:993-996.
19. Piehl S., Heberer T., Balizs G., Scanlan T., Köhrle J. Development of a validated liquid chromatography/tandem mass spectrometry method for the distinction of thyronine and thyronamine constitutional isomers and for the identification of new deiodinase substrates. Rapid Commun. Mass Spectrom. 2008, 22:3286-3296.
20. Kazemifard A., Moore D., Aghazadeh A. Identification and quantitation of sodium-thyroxine and its degradation products by LC using electrochemical and MS detection. J. Pharm. Biomed. Anal. 2001, 25:697-711.
21. Tzanavaras P., Themelis D., Zotou A., Stratis J., Karlberg B. Optimization and validation of a dissolution test for selegiline hydrochloride tablets by a novel rapid HPLC assay using a monolithic stationary phase. J. Pharm. Biomed. Anal. 2008, 46:670-675.